Immune thrombocytopenic purpura secondary to SARS-CoV-2 infection in a child with acute lymphoblastic leukaemia: a case report and review of literature.

• 发表时间: Nov 2021 5
• 来源期刊: BMJ Case Rep
• DOI: 10.1136/bcr-2021-245869
• PMID: 34740909
• 文章类型: Case Reports
• 作者列表: Dongre A,Jameel PZ,Deshmukh M,Bhandarkar S

关键词: haematology (incl blood transfusion); paediatric oncology

Mesh: COVID-19; Child; Child, Preschool; Female; Humans; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications drug therapy; Purpura, Thrombocytopenic, Idiopathic / complications diagnosis drug therapy; SARS-CoV-2

Abstract

Immune thrombocytopenic purpura (ITP) is characterised by isolated thrombocytopenia which may be idiopathic or due to a secondary aetiology. ITP is being increasingly recognised secondary to SARS-CoV-2 infection in the current pandemic. Here, we report a case of a five-and-a-half-year-old female child on maintenance chemotherapy for acute lymphoblastic leukaemia who subsequently developed ITP secondary to SARS-CoV-2 infection. Our patient had prolonged thrombocytopenia secondary to ITP, requiring the use of second-line agents including romiplostim and eltrombopag. This is a unique case where ITP was recognised secondary to SARS-CoV-2. In such cases of thrombocytopenia, ITP should be considered as an important differential in addition to relapse of leukaemia or thrombocytopenia due to chemotherapy drugs.